Chapel Hill, NC, April 20, 2011 - PharPoint Research, Inc., a drug development service company providing biostatistics and data management services to the pharmaceutical and biotechnology industries, launches ‘Target SAE System’, an electronic solution for the management of serious adverse events (SAE) and the integration of these data with other safety data collected in clinical trials.
‘Target SAE System’ provides the necessary framework to fully integrate SAE management and data analysis thereby providing our clients the ability to perform the necessary aggregate analyses to provide true safety surveillance and informed signal detection”, stated Jennifer A. Elder, PhD, PharPoint Chief Scientific Officer. “The launch of ‘Target SAE System’ is timely as the FDA has called for cooperation and implementation of its ‘Final Rule’ by 28 September 2011.”
Audra McRae, PharPoint Chief Operating Officer commented, “PharPoint is well-positioned to offer this capability. By integrating the serious adverse event reporting component with our vast experience in data management and data analysis, PharPoint places itself in the best position to give our sponsors the timely reporting of individual events as well as the aggregate data analysis they need to ensure compliance with federal regulations.”
About PharPoint Research
PharPoint Research, Inc. is a niche pharmaceutical development service provider specializing in data management and biostatistics. PharPoint understands the importance of providing responsiveness and high-quality, timely deliverables to customers. The PharPoint team offers solid industry expertise based on many years of experience and has a proven ability to consistently exceed client expectations. Founded in 2006, PharPoint has two locations: Chapel Hill, NC near Research Triangle Park and Wilmington, NC. For more information, visit www.pharpoint.com.
Contact:
PharPoint Research, Inc
Megan O’Keefe
919.929.0012
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
